Overview

Iatrogenic harm is harm caused by the treatment itself. The word comes from the Greek iatros (doctor) and genesis (origin): adverse outcomes produced not by the original condition but by diagnosis, medication, surgery, or institutional medical practice. It is one of medicine's oldest paradoxes — the expectation that treatment will benefit, not damage.

In gender medicine, the term describes permanent physical changes, lost fertility, sexual dysfunction, and psychological injury caused by transition interventions that were provided without adequate assessment, honest risk disclosure, or genuine informed consent. A 2023 commentary argues the medical community should recognise detransitioners as survivors of iatrogenic harm who need personalised care (Jorgensen 2023).

Historical context

Iatrogenic scandals are not hypothetical. Documented medical misadventures include cardiac valvular damage from appetite suppressants (fen-phen), excess heart attacks and strokes from certain anti-inflammatories (Vioxx), and the opioid overdose epidemic — each initially defended as safe and effective before the harm became undeniable (Jorgensen 2023).

The paradox of iatrogenic harm is that it "defies our expectations about medicine; our expectations that medicine will benefit, rather than harm us" (Sharpe & Faden 1998, quoted in Jorgensen 2023). Gender medicine, critics argue, now shows the same pattern: a widely deployed intervention whose long-term harms are systematically under-measured.

Mechanisms of harm

Harm is not simply "transition went wrong." It occurs through identifiable clinical failures:

Inadequate assessment

Underlying trauma, mental illness, dissociation, autism, and internalised homophobia or misogyny are often not explored before medicalisation. In a Finnish clinic study of nine detransitioners, all reported their transition was driven by unresolved psychological stressors — childhood trauma, sexual abuse, eating disorders, borderline personality symptoms — not genuine gender dysphoria (Kettula et al. 2025). A psychoanalytic case study found gender dysphoria functioning as a defence against unmetabolised grief and attachment trauma (Marchiano 2021).

Defective informed consent

Risks and permanence are routinely understated. In a survey of 100 detransitioners, 55% felt their initial evaluation was inadequate and nearly half said counselling was overly positive about benefits while downplaying risks (Littman 2021). A case report documented a woman who was never told that chest masculinisation mastectomy would permanently destroy her ability to breastfeed — grief that emerged only years later when she became pregnant (Gribble, Bewley & Dahlen 2023).

Irreversible intervention on a changing identity

Adolescent identity is not fixed. The Cass Review (2024), England's independent review of youth gender services, found the evidence base for youth medical transition weak and warned against irreversible interventions on developing identities. A Norwegian cohort study found 97% of those given puberty blockers proceeded to hormones — raising the question of whether "pause for exploration" functions in practice as a conveyor belt (Nyquist et al. 2025, retracted 2026).

Abandonment after harm

Detransitioners frequently report being dropped by the clinics that treated them. A 2022 survey of 237 detransitioners found widespread unmet medical needs, negative experiences with providers, and only 18% who felt they received enough support (Vandenbussche 2022). Only 24% of detransitioners inform their clinicians of detransition at all (Littman 2021) — meaning clinic records systematically undercount harm.

The iatrogenic harm cycle

A 2025 paper extends the concept further, arguing that iatrogenesis operates at every stage — not just treatment, but the production of cases (Kaltiala-Heino et al. 2025). The proposed cycle:

1. Early social transition is not a neutral act. Affirming a child's social transition can convert what might have been a temporary phase into a fixed identity, increasing persistence rates and channelling children toward a medical pathway (Cass 2024; Zucker 2020).
2. Puberty blockers may iatrogenically increase persistence — 97% of blocked youth proceed to hormones (Nyquist et al. 2025, retracted 2026) — while carrying their own harms to bone, brain, fertility, and sexual function (Miroshnychenko et al. 2025).
3. Hormones and surgery then produce irreversible bodily changes, lifelong hormone dependence, and — in some patients — a new distress: iatrogenic gender dysphoria or "reverse dysphoria," discomfort with the very sex characteristics treatment created (MacKinnon et al. 2023).

On this account, gender dysphoria cases are "encircled by an iatrogenic harm cycle, from development to treatment" (Kaltiala-Heino et al. 2025).

Psychological harm: PTSD and moral injury

The harm is not only physical. A 2026 paper by psychiatrists Clayton and McDeavitt argues that for some detransitioners, the medical transition itself constitutes a traumatic event meeting criteria for post-traumatic stress disorder (PTSD) (Clayton & McDeavitt 2026).

PTSD

Upon detransition, previously desired changes can become deeply traumatizing — "intense feelings, including horror, helplessness, anguish, despair, self-disgust, betrayal, rage, guilt, and shame." A self-concept of "a clean and honorable woman" may shift to "a mutilated woman and/or abused child, robbed of her sexuality and injured for life" (Clayton & McDeavitt 2026). Crucially, consent does not preclude trauma: an event one sought and assented to can later be experienced as catastrophic.

Moral injury

Moral injury — incorporated into the DSM-5-TR in 2025 under code Z65.8 — describes "the psychological damage inflicted on an individual upon realizing a profound betrayal by individuals in positions of authority." When harm is inflicted by trusted caregivers, PTSD risk is heightened and symptoms worsen. Detransitioners who feel betrayed by clinicians, or by a medical profession that inadequately regulated the field, may suffer moral injury alongside PTSD — and PTSD with moral injury is particularly difficult to treat unless the betrayal is acknowledged (Clayton & McDeavitt 2026).

Clinician dismissiveness deepens the injury. When influential gender clinicians call "detransition" itself "invalidating," or tell young women who want breasts back to "just go and get them," the moral injury compounds (Clayton & McDeavitt 2026).

What detransitioners describe

Detransitioners use the language of medical harm consistently: being fast-tracked, being assessed by clinicians who never questioned the trans narrative, discovering permanence after the fact, and struggling to find providers who will help with reversal.

I'm basically the result of a medical experiment I didn't know was an experiment when I participated. That could be you too if you go ahead with HRT. —UniquelyDefined, detrans male.

I was left with permanent breast pain. That was not in any of the warnings or medical literature. No one knows what to do with me now. —UniquelyDefined, detrans male.

I was 15 and the doctors knew about my mental health history with bad OCD... Who I do blame is the doctors who we trusted. The therapists who didn't question me at all. Who made me think almost everything is gonna get better after testosterone and top surgery. —ClydeFallon, detrans female.

My own doctor said "We know very little about detransition." Then maybe don't use teenagers as your experimental guinea pigs for cross sex hormones and surgery. —Due-Intention-6778, detrans female.

I told them, point blank, T wasn't for me and they still told me to try it. When I was on it and I expressed doubts, they encouraged me to continue, multiple times. My body is forever changed because of them. —Dismal_Plant_8360, detrans female.

I was prescribed estrogen and puberty blockers when I was 16. Only two hour long appointments with a psychiatrist... I had a history of being abused... I was hospitalized when I was 14 for suicidal ideation and severe self harm. … Somehow none of this was ever looked into. —Dear-Shift-7636, detrans male.

The key differences between transition regret and plastic surgery regret lie in the effects of the treatments and the framing by medical providers. Plastic surgery generally does not result in sterility, endocrine disruption, or loss of sexual function. Transition often does... Transition regret is so severe because of both the physical medical complications and the sense of betrayal and having been misled by those entrusted to care for you. —writteno, detrans female.

Physical harms described

Detransitioners report a wide range of lasting physical effects, often ones never disclosed to them:

• Females on testosterone: voice deepening, facial hair, male-pattern baldness, vaginal atrophy, cervical prolapse, high blood pressure, weight gain, high cholesterol, autoimmune conditions, hysterectomy encouraged for pain caused by the hormones themselves (blitz-angel; sodacatcicada).
• Males on estrogen: permanent breast tissue and breast pain, testicular atrophy, erectile dysfunction, destroyed sexual function, lost fertility, bone density loss, muscle atrophy (MythicalDawn; d1no__).
• After puberty blockers: impaired bone density, ovarian dysfunction, "dipping out of menopause range," stunted organ development (DetransIS).
• After surgery: lost breastfeeding capacity, phantom limb sensations, permanent scarring, destroyed sexual function (blueyedreamr; Gribble, Bewley & Dahlen 2023).

Fertility and sexual function

Two forms of iatrogenic harm come up repeatedly in detransitioners' accounts, and are often described there as poorly explained at the point of consent, that they have their own pages in this section. Both are harms to functions that some patients had not yet thought about, or for young patients had never experienced, when they agreed to treatment.

Fertility

Each intervention affects the ability to have biological children differently. Hormones taken after a completed puberty often, but not always, leave fertility recoverable after stopping. Puberty blockers started in early puberty and followed directly by cross-sex hormones are expected to prevent eggs or sperm from ever maturing, and because almost all blocked young people go on to hormones (Nyquist et al. 2025, retracted 2026), this is the usual path rather than an edge case. Removing the ovaries, uterus or testes ends natural fertility permanently, and mastectomy ends the ability to breastfeed (Gribble, Bewley & Dahlen 2023). Uptake of fertility preservation before treatment is low. The fertility page covers the evidence for each intervention, pregnancies after detransition, and the grief some detransitioners describe over children they may not be able to have.

Sexual function

Cross-sex hormones act directly on genital tissue and on desire. In females, testosterone can cause vaginal atrophy, painful sex and pelvic pain alongside permanent clitoral growth; in males, estrogen and testosterone blockers can reduce libido, erections, ejaculation and orgasm, and cause testicular atrophy. Young people blocked early in puberty may never go through sexual maturation at all, and genital surgeries remove or reconstruct the organs through which sexual sensation is experienced. Some of these effects recover after stopping hormones and some do not. The sexual function page sets out what is known, what recovers, and why some detransitioners describe these effects as some of the least explained consequences of their transition.

Evidence and counter-arguments

The evidence base is genuinely contested, and honesty requires saying so.

What systematic reviews show

Systematic reviews find the certainty of evidence for both benefits and harms of youth gender medicine to be "very low" (Miroshnychenko et al. 2025; Miroshnychenko et al. 2025). This cuts both ways: it cannot confirm benefit, and it cannot confirm the scale of harm. A 2024 systematic review of detransition prevalence found rates of 1.6–9.8% for hormone discontinuation but concluded the literature is too heterogeneous and short-term to draw firm conclusions (Feigerlova 2025).

Discontinuation is not the same as harm

Critics of the iatrogenic-harm framing note that treatment discontinuation does not equal regret or injury — people stop hormones for financial, access, or health reasons too (Jorgensen 2023 limitations). A US military cohort study found ~30% discontinuation within 4 years but could not determine why patients stopped (Roberts et al. 2022).

Loss to follow-up

Studies with high loss to follow-up systematically underestimate harm. Only 24% of detransitioners inform their clinicians (Littman 2021); the Norwegian study acknowledges its detransition figure is "probably an underestimate" for exactly this reason (Nyquist et al. 2025, retracted 2026). The honest position is that we do not have good long-term outcome data either way — and that uncertainty itself is a consent problem (Cohn 2023).

Minority stress and contrary views

Some researchers argue that framing transition as iatrogenic harm overstates causation and dismisses minority-stress explanations for poor mental health outcomes (the idea that stigma and discrimination themselves harm minority groups' mental health). Others counter that "minority stress" is often used to explain away complex psychological conditions that should have been assessed before medicalisation (Jorgensen 2023). Both claims deserve scrutiny; neither is settled.

Ethical analysis

Nonmaleficence and the autonomy shift

Bioethicists note a shift in how youth gender medicine is justified: from evidence-based health outcomes toward autonomy-based "embodiment goals" — the idea that a patient's desire for particular sex characteristics is itself sufficient justification. Gorin (2024) argues this contradicts medicine's foundational commitment to nonmaleficence (do no harm): patient desire for body modification is not sufficient justification for risky intervention without evidence of health benefit (Gorin 2024).

Consent under uncertainty

Genuine informed consent requires knowing the risks. When even clinicians admit they do not know the long-term effects of cross-sex hormones — as detransitioners report their doctors telling them — consent becomes structurally defective. As one detransitioner put it: "No one can have informed consent because even the professionals are not fully informed on what HRT does to their patient" (watching_snowman).

The duty to follow up

A medical system that initiates irreversible treatment has an ethical obligation to track outcomes, including negative ones. The fact that most detransitioners never inform their clinicians — and that clinics rarely seek them out — represents a systemic failure of surveillance (MacKinnon et al. 2023).

What would reduce iatrogenic harm

Detransitioners and researchers converge on several demands:

• Thorough psychological assessment first — exploring trauma, dissociation, autism, OCD, eating disorders, and sexuality before any medical step (Kettula et al. 2025; Cass Review 2024).
• Honest risk disclosure — including permanence, fertility loss, sexual dysfunction, and the fact that long-term data is sparse (Littman 2021).
• Gender exploratory therapy as a genuine alternative to affirmation — not conversion therapy, but open exploration of what the distress means (D'Angelo 2025; see gender exploratory therapy).
• Long-term follow-up of all patients, including those who disengage (MacKinnon et al. 2023).
• Clinical competence in detransition care — providers who can manage lasting hormonal and surgical effects without stigma (Vandenbussche 2022).

Related pages

• Informed consent critique
• Detransition
• Gender exploratory therapy
• Puberty blockers
• Testosterone in females
• Estrogen & testosterone blockers in males
• Top surgery regret
• Fertility
• Sexual function

References

• Jorgensen, S. C. J. (2023). Iatrogenic Harm in Gender Medicine. Journal of Sex & Marital Therapy. study page, source.
• Kaltiala-Heino et al. (2025). Iatrogenic Gender Dysphoria and Harm Cycle in Gender Affirming Care. Journal of Sex & Marital Therapy. source.
• Clayton, A. & McDeavitt, J. (2026). Detransition, Posttraumatic Stress Disorder, and Moral Injury. Archives of Sexual Behavior. source.
• Kettula, K. et al. (2025). Gender Dysphoria and Detransitioning in Adults: An Analysis of Nine Patients from a Gender Identity Clinic from Finland. study page.
• Marchiano, L. (2021). Gender detransition: a case study. study page.
• Littman, L. (2021). Individuals Treated for Gender Dysphoria with Medical and/or Surgical Transition Who Subsequently Detransitioned: A Survey of 100 Detransitioners. study page.
• Gribble, K. D., Bewley, S. & Dahlen, H. G. (2023). Breastfeeding grief after chest masculinisation mastectomy and detransition. study page.
• Cass, H. (2024). Independent review of gender identity services for children and young people. study page.
• Nyquist, C. B. et al. (2025). Treatment trajectories among children and adolescents referred to the Norwegian National Center for Gender Incongruence. study page.
• Vandenbussche, E. (2022). Detransition-Related Needs and Support: A Cross-Sectional Online Survey. study page.
• Miroshnychenko, A. et al. (2025). Puberty blockers for gender dysphoria in youth: A systematic review and meta-analysis. study page.
• Miroshnychenko, A. et al. (2025). Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years. study page.
• Feigerlova, E. (2025). Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review. study page.
• Roberts, C. M. et al. (2022). Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. study page.
• Cohn, J. (2023). The Detransition Rate Is Unknown. study page.
• Gorin, M. (2024). The Aims of Medicine in Pediatric Gender Care: Against the Autonomy-Based View. study page.
• MacKinnon, K. R. et al. (2023). Detransition needs further understanding, not controversy. study page.
• D'Angelo, R. (2025). Do we want to know?. study page.
• Sharpe, V. & Faden, A. (1998). Medical harm: historical, conceptual and ethical dimensions of iatrogenic illness. Cambridge University Press.